Siemens Healthcare Partners with Pfizer to Develop Companion Diagnostics
|
By LabMedica International staff writers Posted on 11 Feb 2014 |
|
Siemens Healthcare Diagnostics, of Siemens Healthcare (Erlangen, Germany), has entered into a collaboration agreement with the global, research-based pharmaceutical company Pfizer (New York City, NY, USA), to design, develop, and commercialize diagnostic tests for therapeutic products across Pfizer’s pipeline. Under the agreement, Siemens will be one of Pfizer's collaboration partners to develop and provide in vitro diagnostic tests for use in clinical studies and, potentially, eventual global commercialization with Pfizer products.
The Siemens Clinical Laboratory (SCL), a high-complexity testing laboratory focused on advancing personalized medicine, will develop the companion diagnostic tests under this partnership. The collaboration will leverage Siemens' worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories, and point-of-care settings to help enable diagnostics development.
"Companion diagnostics are an important enabler of targeted therapies for patients," said John Hubbard, senior vice president and Worldwide Head of Development Operations at Pfizer. “This agreement with Siemens Healthcare Diagnostics is another example of Pfizer's commitment to develop new precision medicines to address unmet clinical needs." Companion diagnostic tests are clinical tests linked to a specific drug or therapy, intended to assist physicians in making more informed and personalized treatment decisions for their patients. When used in the drug development process, companion diagnostics may help pharmaceutical companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.
"Our relationship with Pfizer marks a major milestone in Siemens' personalized medicine strategy," said Dr. Trevor Hawkins, Senior Vice President, Strategy & Innovations, Diagnostics Division, Siemens Healthcare; "We look forward to collaborating with Pfizer to realize the goal of advancing innovative solutions that change the way patient care is delivered and together shape the future of diagnostic medicine."
Related Links:
Siemens Healthcare
Pfizer
The Siemens Clinical Laboratory (SCL), a high-complexity testing laboratory focused on advancing personalized medicine, will develop the companion diagnostic tests under this partnership. The collaboration will leverage Siemens' worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories, and point-of-care settings to help enable diagnostics development.
"Companion diagnostics are an important enabler of targeted therapies for patients," said John Hubbard, senior vice president and Worldwide Head of Development Operations at Pfizer. “This agreement with Siemens Healthcare Diagnostics is another example of Pfizer's commitment to develop new precision medicines to address unmet clinical needs." Companion diagnostic tests are clinical tests linked to a specific drug or therapy, intended to assist physicians in making more informed and personalized treatment decisions for their patients. When used in the drug development process, companion diagnostics may help pharmaceutical companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.
"Our relationship with Pfizer marks a major milestone in Siemens' personalized medicine strategy," said Dr. Trevor Hawkins, Senior Vice President, Strategy & Innovations, Diagnostics Division, Siemens Healthcare; "We look forward to collaborating with Pfizer to realize the goal of advancing innovative solutions that change the way patient care is delivered and together shape the future of diagnostic medicine."
Related Links:
Siemens Healthcare
Pfizer
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Latest Industry News
- Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business
- Agilent Completes Acquisition of Digital Pathology Platform Developer Proscia
- New Diagnostics Company Onvaro Formed to Expand Decentralized Testing
- Illumina Selected to Support National Genomics Study for Personalized Healthcare in Singapore
- Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk
- CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries
- Real Diagnostics Adds Saliva-Based Periodontal Testing With SimplyTest Deal
- Collaboration Brings Tumor-Informed MRD Monitoring to Breast Cancer Care in Abu Dhabi
- Qiagen Agrees to Go Private Through EQT-Led Acquisition
- Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe
- Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
- Myriad Genetics to Sell Prenatal Testing Portfolio to Labcorp
- Alzheimer’s Progression Blood Test Gains U.S. Patent Ahead of Planned Launch
- Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition
- Labcorp Acquisition to Strengthen Specialty Testing and Prostate Cancer Assessment
- Collaboration Advances Genomic Instability Biomarker for Prostate Cancer
Channels
Clinical Chemistry
view channel
Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging
Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more
Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury
Kidney function monitoring in breast cancer care often relies on serum creatinine, a routine blood marker used to estimate renal function. However, creatinine increases in patients receiving abemaciclib... Read more
Blood-Based Score May Support Targeted Interventions for Healthier Aging
Chronic diseases frequently accumulate with age, complicating efforts to maintain functional independence in older adults. Studies cited by the investigators indicate that about 60% of people over age... Read more
Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read moreMolecular Diagnostics
view channel
Comprehensive Tumor Profiling Uncovers Overlooked Hereditary Cancer Risk Genes
Patients with solid tumors often undergo molecular profiling to identify alterations that can guide therapy. This testing may also reveal constitutional cancer-predisposing DNA variants, which are present... Read more
Nonendoscopic Methylation Assay Enables Rapid Barrett’s Esophagus Screening
Millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, are at risk of developing esophageal precancer and cancer. Nonendoscopic sample collection may support... Read more
Hematology
view channel
New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients
Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more
Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers
Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways
Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more
Roche Gains FDA Clearance for Flexible Respiratory Pathogen Panel
Respiratory infections often cause overlapping viral and bacterial symptoms, making diagnosis more difficult during peak respiratory seasons. This uncertainty can be especially important for high-risk... Read more
Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
T-follicular helper cell lymphoma (TFHL) is a subtype of peripheral T-cell lymphoma associated with poor prognosis and limited treatment options after relapse. Its molecular abnormalities include frequent... Read more
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read moreMicrobiology
view channel
Stool Testing Predicts UTI Risk and Guides Antibiotic Selection
Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more
Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections
Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more
Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births
Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more
Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read morePathology
view channel
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Technology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
